Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
12/2005
12/22/2005US20050281796 Targeting damaged lung tissue
12/22/2005US20050281795 Controlled release formulations of enzymes, microorganisms, and antibodies with mucoadhesive polymers
12/22/2005US20050281789 Transcutaneous and/or transdermal transport of materials
12/22/2005US20050281778 Human growth hormone conjugated with biocompatible polymer
12/22/2005US20050281777 Photo-triggered release of active substances from dendrimer-photosensitizer complexes
12/22/2005US20050281755 Topical foam/mousse compositions for treating psoriasis
12/22/2005US20050281750 Sprayable compositions comprising a combination of pharmaceutical active agents, an alcohol phase, at least one volatile silicone and a non-volatile oily phase
12/22/2005DE10212864B4 Polymermatrizes umfassend ein Mischsystem zur Löslichkeitsvermittlung von pharmazeutischen Wirkstoffen, Verfahren zu deren Herstellung und deren Verwendung Polymer matrices comprising a mixing system for the solubilization of pharmaceutically active substances, processes for their preparation and their use
12/22/2005DE102004045186A1 Hydratisierte lamellare Phasen oder Liposomen, enthaltend ein Fettmonoamin oder ein kationisches Polymer, das die intrazelluläre Penetration begünstigt, und kosmetische oder pharmazeutische Zusammensetzungen, diese enthaltend, sowie Screeningverfahren nach einer solchen Substanz Hydrated lamellar phases or liposomes, containing a fatty mono-amine or a cationic polymer that promotes intracellular penetration, and cosmetic or pharmaceutical compositions comprising them, as well as screening methods for such substance
12/22/2005DE10053267B4 Verfahren zur Herstellung von mikrosphärischen Kristalliten, danach hergestellte mikrosphärische Kristallite und deren Verwendung A process for producing microspherical crystallites which microspherical crystallites produced thereby, and their use
12/22/2005DE10042412B4 Transceiver for bus subscriber of bus system of building system engineering, has two wires, where microcontroller is connected with receiver unit over connection on one hand, which is connected to two wires of bus system
12/22/2005CA2609260A1 Rna-containing microvesicles and methods therefor
12/22/2005CA2570649A1 Pharmaceutical composition containing a stable and clear solution of anti-inflammatory drug in soft gelatin capsule and process for producing the same
12/22/2005CA2569788A1 Tumor specific antibody
12/22/2005CA2569746A1 Capsule stable against mastication
12/22/2005CA2569684A1 Dry composition for oral ingestion and gel composition prepared just before use for oral ingestion
12/22/2005CA2569672A1 Polypeptides with the capacity to entrap drugs and release them in a controlled way
12/22/2005CA2569645A1 Cationic lipids and methods of use
12/22/2005CA2569352A1 Morinda citrifolia-based formulation 5-lox and 15-lox
12/22/2005CA2569137A1 Intranasal formulations of interferon beta free of stabilizers that are proteins or polypeptides
12/22/2005CA2569072A1 Preparation for localized delivery of therapeutic agent
12/22/2005CA2567835A1 Novel sulfonamides as inhibitors of histone deacetylase for the treatment of disease
12/22/2005CA2567827A1 Pharmaceutical compositions comprising polyethylene glycol having a molecular weight of less than 600 daltons
12/22/2005CA2558676A1 Compositions and methods for topical diagnostic and therapeutic transport
12/22/2005CA2510813A1 Injectable pharmaceutical compositions comprising sodium diclofenac and .beta.-cyclodextrin
12/21/2005EP1607407A2 Aloe pectins
12/21/2005EP1607085A1 Sustained-release hydrogel preparation
12/21/2005EP1606997A1 Method of inhibiting freeze concentrating of substance in wet material, method of inhibiting deactivation of physiologically active substance, and process for producing lyophilizate or frozen matter having component homogeneously diffused therein
12/21/2005EP1606381A2 Coated enzyme granules
12/21/2005EP1606349A2 Controlled release polymeric gels
12/21/2005EP1606301A2 Aptamer therapeutics useful in ocular pharmacotherapy
12/21/2005EP1606298A2 Direct compressible trehalose solids
12/21/2005EP1605982A2 Compositions for neuronal tissue regeneration
12/21/2005EP1605977A1 Pharmaceutical composition comprising fungal cell or fragment thereof
12/21/2005EP1605968A2 Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides
12/21/2005EP1605967A1 Novel nph insulin preparations
12/21/2005EP1605964A1 TARGETED PROTEIN DEGRADATION VEHICLES (TPDVs), NUCLEIC ACID CONSTRUCTS ENCODING THEM AND THEIR USE
12/21/2005EP1605956A1 Administration of capsaicinoids
12/21/2005EP1605953A2 Heterobifunctional polymeric bioconjugates
12/21/2005EP1605948A1 Prostaglandin compositions for the treatment of erectile dysfunction
12/21/2005EP1605945A1 Topical formulation and use of buspirone
12/21/2005EP1605931A1 Drug formulations having long and medium chain triglycerides
12/21/2005EP1605928A1 Compositions and methods for treatment of premature ejaculation
12/21/2005EP1605913A2 Angiogenesis promotion by prostaglandin compositions and methods
12/21/2005EP1605900A2 Use of benzyl alcohol, and other phenolic preservatives to reduce pain during intradermal injection
12/21/2005EP1605897A2 Polyethelene glycol link glp-1 compounds
12/21/2005EP1605895A2 Oral insulin therapies and protocol
12/21/2005EP1605894A2 Oxytocin controlled release formulations and methods of using same
12/21/2005EP1605893A2 Trans-membrane-antibody induced inhibition of apoptosis
12/21/2005EP1605847A2 Antibody-targeted photodynamic therapy
12/21/2005EP1605776A1 Method and composition for preventing or reducing diarrhea
12/21/2005EP1465665B1 Water-soluble stabilized self-assembled polyelectrolytes
12/21/2005EP1443968A4 Edible film
12/21/2005EP1429780B1 Method of treating middle ear infections
12/21/2005EP1373366B1 Multi-arm block copolymers and pharmaceutical compositions
12/21/2005EP1364208B1 Conjugates of defined stoichiometry
12/21/2005EP1362039B1 Heterocyclic substituted carbonyl derivatives and their use as dopamine d3 receptor ligands
12/21/2005EP1313738B1 Process for the preparation and purification of thiol-containing maytansinoids
12/21/2005EP1282429A4 Pharmaceutical gel composition
12/21/2005EP1282402B1 Stabilized aqueous suspensions for parenteral use
12/21/2005EP1265930A4 Cyclodextrin dimers with spacers having peptide structures for encapsulation of pharmaceutically active substances with potential high side-effects
12/21/2005EP1250161B1 Polymer blends as biodegradable matrices for preparing biocomposites
12/21/2005EP1223915B1 Dry powder compositions having improved dispersivity
12/21/2005EP1213974B1 Directly compressable raw material for tablets
12/21/2005EP1180015B1 Generation of therapeutic microfoam
12/21/2005EP1171096B1 Cosmetic preparations
12/21/2005EP0809705B1 Nucleic acid-containing composition, preparation and use thereof
12/21/2005EP0785772A4 Lyophilizate of lipid complex of water insoluble camptothecins
12/21/2005CN1711111A Thrombin-carrying bioabsorbable synthetic nonwoven fabric
12/21/2005CN1711109A Positional isomers of PEG IFN alpha 2a
12/21/2005CN1711108A Method for the selective and quantitative functionalization of immunoglobulin Fab fragments, conjugate compounds obtained with the same and compositions thereof
12/21/2005CN1711106A Agents for the diagnosis and treatment of tumours that expose altered proteins on the cell surface
12/21/2005CN1711104A An aqueous pharmaceutical formulation comprising the thrombin inhibitor melagatran and use of the formulation in the manufacture of a medicament for use by nasal administration in treating thromboemb
12/21/2005CN1711074A Liposomes
12/21/2005CN1709516A High water-soluble prodrug, and its preparing method and pharmaceutical use
12/21/2005CN1709515A Stable liquid compound fibrillarin blocking agent, and its preparation and use
12/21/2005CN1709514A Lipophilic medicine hydroxypropyl beta cyclodextrin clathrate preparing method
12/21/2005CN1709513A Method for producing medicine without bitter taste and peculiar smell
12/21/2005CN1709512A Magnetic nano drug carrier, and its preparing method and use
12/21/2005CN1709511A Drug-carrier calcium phosphate hano line and its preparing method
12/21/2005CN1232623C Method for moistening contact lens and low ionic strength ophthalmic compositions used therefor
12/21/2005CN1232563C Poly acid anhydride for release-controlled medicine carrier and method for producing the same
12/21/2005CN1232539C Match of organic medicine and beta-cyclodextrin derivative and its preparing process
12/21/2005CN1232305C Aseptics
12/21/2005CN1232252C Retard release preparation containing alpha-lipoic acid (derivatives)
12/21/2005CN1232248C Combined sustained release agent and preparation thereof for preventing and treating livestock helminth, acarid and ectosarc disease
12/21/2005CN1232245C Preparation containing active ingredients and/or auxiliary agents with a controlled release of these substances and the use and production of the same
12/21/2005CN1232244C Stable non-aqueous single phase viscose carrier and formulations utilizing such carrier
12/20/2005US6977257 Aripiprazole oral solution
12/20/2005US6977249 molecular weight reduction of dextran by hydrolysis, hydrogenation, and oxidation; complexing with ferric oxy-hydroxide; narrow molecular weight distribution controlled by the ratio of hydrogenated/oxygenated groups; improved stability; anemia
12/20/2005US6977075 Administering to a patient having a disorder associtaed with an intracellular pathogen, a molecular conjugate of a photosensitizer and a targeting moiety, wherein the targeting moiety targets conjugate to the pathogen or infected cell
12/20/2005CA2322432C Pharmaceutical composition containing cefuroxime axetil stable for moisture absorption
12/20/2005CA2199778C Extended release formulation of venlafaxine
12/20/2005CA2130305C Distribution device for a therapeutical or cosmetic substance on a volatile polydiorganosiloxane inert carrier; composition usable in said device
12/15/2005WO2005119255A2 Constrained cis-diol-borate bioconjugation system
12/15/2005WO2005118782A2 Methods of promoting cardiac cell proliferation
12/15/2005WO2005118702A2 Unagglomerated core/shell nanocomposite particles
12/15/2005WO2005118672A1 Polymer based nano-carriers for the solubilization and delivery of hydrophobic drugs
12/15/2005WO2005118642A2 Bispecific fusion antibodies with enhanced serum half-life
12/15/2005WO2005118627A2 Griffithsin, glycosylation-resistant griffithsin, and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of use
1 ... 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 ... 1712